Abstract
Parkinson disease, the second most common movement disorder, is a complex neurodegenerative disorder hallmarked by the accumulation of alpha-synuclein, a neural-specific small protein associated with neuronal synapses. Mutations in the glucocerebrosidase gene (GBA1), implicated in the rare, autosomal recessive lysosomal disorder Gaucher disease, are the most common known genetic risk factor for Parkinson disease. Insights into the inverse relationship between glucocerebrosidase and alpha-synuclein have led to new therapeutic approaches for the treatment of Gaucher disease and GBA1-associated Parkinson disease. Unlike the current drugs used to treat Gaucher disease, which are highly expensive and do not cross the blood-brain-barrier, new small molecules therapies, including competitive and non-competitive chaperones that enhance glucocerebrosidase levels are being developed to overcome these limitations. Some of these include iminosugars, ambroxol, other competitive glucocerebrosidase inhibitors, and non-inhibitory chaperones or activators that do not compete for the active site. These drugs, which have been shown in different disease models to increase glucocerebrosidase activity, could have potential as a therapy for Gaucher disease and GBA1- associated Parkinson disease. Some have been demonstrated to reduce α-synuclein levels in pre-clinical studies using cell-based or animal models of GBA1-associated Parkinson disease, and may also have utility for idiopathic Parkinson disease.
Introduction
Gaucher disease (GD), first described in 1882 by Dr. Phillipe Gaucher, is an inborn error of metabolism due to mutations in the gene GBA1, encoding the lysosomal enzyme glucocerebrosidase (GCase) (). GCase, a lysosomal hydrolase, cleaves both glucosylceramide (GlcCer) to ceramide and glucose, and glucosylsphingosine (GlcSph) into sphingosine and glucose. This rare autosomal recessive inherited disorder occurs in approximately 1:40,000–60,000 live births in the general population, whereas among Ashkenazi Jews the frequency increases to around 1:850 (). In patients with GD, “Gaucher cells,” macrophages engorged with lysosomal GlcCer, present in the spleen, liver, and bone marrow, lead to organomegaly and inflammation (; ; ). Clinically, there are three types of GD. Type 1 or non-neuronopathic GD presents with organomegaly, bone manifestations, anemia, and thrombocytopenia (; ). Acute neuronopathic GD2, the rarest form with devastating and progressive neurodegeneration including bulbar findings, seizures, and opisthotonos, results in death during infancy or early childhood (; ; Weiss et al., 2015). Chronic neuronopathic GD3 is characterized by a slower progression of neurological symptoms, with a later onset. These patients have extensive visceral and skeletal involvement, but also may exhibit myoclonic epilepsy, ataxia, impaired eye movements, developmental delay, or intellectual deterioration (, ; ; Sidransky and Lopez, 2012). There is considerable phenotypic variation within each type of GD, including rare patients who develop Parkinson disease (PD).
Parkinson disease, first described in 1817 by James Parkinson, is found in 2–3% of individuals over age 65 (). This disease is characterized by the loss of dopaminergic (DA) neurons in the substantia nigra, as well as by Lewy bodies containing alpha-synuclein (α-Syn) (Spillantini et al., 1997; Surmeier et al., 2017), which ultimately result in the classically associated symptoms, tremor, postural instability, bradykinesia, and rigidity (). Currently, mutations in GBA1 are one of the most common genetic risk factors for PD, as well as dementia with Lewy bodies (DLB). Mutations in GBA1 were found in 5–20% of sporadic PD cases with an estimated odds ratio of 5.4. In DLB the odds ratio was 8.3 (Sidransky et al., 2009; ; ). Patients with GBA1-associated PD (GBA1-PD) resemble those with sporadic PD but exhibit an earlier disease onset. The lysosome, the central player uniting GD and PD, is the main organelle responsible for α-Syn degradation (). While the mechanism underlying the association between GD and PD still remains controversial, one hypothesis proposed posits that elevated substrate levels resulting from diminished GCase could stabilize soluble oligomeric α-Syn intermediates, enhancing oligomerization and accumulation of α-Syn within lysosomes (Yap et al., 2011; Taguchi et al., 2017). Increased levels of α-Syn in DA neurons could also inhibit the translocation of GCase from the endoplasmic reticulum (ER) to lysosomes which could lead to a gradual increase of the lipid substrates within the lysosome (). This positive feedback loop with the combination of inhibited GCase trafficking and α-Syn accumulation may result in neurodegeneration (; Stojkovska et al., 2018). Furthermore, even patients with PD without GBA1 mutations have lower levels of GCase, suggesting that in idiopathic PD, reduced GCase activity may also contribute to disease progression (; ).
Due to this apparent reciprocal association between GCase and α-Syn, attention is being directed toward designing therapeutics for GD with implications for PD. Currently, patients with type 1 GD are commonly treated with enzyme replacement therapy (ERT) () which alleviates the hematological, visceral, and sometimes skeletal manifestations, but does not cross the blood-brain-barrier, and thus does not impact neurological involvement or PD manifestations (Valayannopoulos, 2013). Substrate reduction therapy (SRT), a second approach for treating GD, focuses on upstream targets, ultimately inhibiting the accumulation of GlcCer (). Two SRT drugs approved by FDA have shown efficacy in type 1 GD (; ) and some cross the blood-brain-barrier. However, the current SRTs have not been efficacious for neuronopathic GD (nGD) (; ; Zimran et al., 2018) and there are several pharmacokinetic limitations ().
Pharmacological chaperones, small molecules designed to bind to a specific target protein and assist in the folding of the protein, are also being developed as an alternative treatment approach for GD or GD-associated PD. They further function by stabilizing the enzyme to prevent misfolding and to enhance accurate translocation of the protein from the ER to the Golgi and lysosome (; ). Since most mutations encountered in GD or GBA1-PD are missense mutations leading to misfolded enzyme, pharmacological chaperones which cross the blood-brain-barrier provide an attractive therapeutic strategy. Here we review studies of chaperones as a treatment for GD and GBA1-PD, focusing on preclinical developments.
Iminosugars
The first chaperone considered for GCase was an iminosugar, N-(n-nonyl) deoxynojirimycin (NN-DNJ). reported that the addition of NN-DNJ to fibroblast culture medium increased the activity of GCase in N370S mutant and wild-type but not L444P mutant cells. However, NN-DNJ also inhibits α-glucosidase and GlcCer synthase, rendering it difficult to use as a target-specific drug. Another iminosugar, α-1-C-Nonyl-DIX that specifically inhibits GCase, but not α-glucosidase, doubled the residual cellular activity of GCase in N370S/N370S fibroblasts (). Bicyclic nojirimycin (NJ) analogs with a sp2-iminosugar structure were found to be stronger chaperones as well as selective and competitive inhibitors of lysosomal GCase (, ; Tiscornia et al., 2013). Some of the new sp2-iminosugar derivatives inhibited enzyme activity by 10-fold at pH 5 ().
Another type of iminosugar, isofagomine (IFG), was reported to bind to the GCase active site, increase GCase activity in cell lysates and restore lysosomal trafficking of GCase in N370S cells (). Incubation of GD patient-derived lymphoblastoid or fibroblast lines with IFG increased GCase activity 3.5- and 1.3-fold and reduced endogenous GlcCer levels (). Testing the effects of IFG on GCase activity in a complex nGD mouse model, 4L;C∗ (V394L/V394L + saposin C−/−) showed that IFG administration extended lifespan and increased GCase activity and protein levels in the brain and visceral tissue, with attenuation of proinflammatory responses (Sun et al., 2011). Further, in vivo tests of IFG in homozygous V394L, D409H, and D409V mice, which are nGD models demonstrated increased GCase activity in visceral tissues and brain extracts (Sun et al., 2012). Whether the effect of IFG on wild-type GCase could be beneficial in synucleinopathies was evaluated using mice overexpressing human wild-type α-Syn (Thy1- α-Syn). Treating with IFG (AT2101) orally for 4 months improved motor function, diminished microglial inflammatory response in the substantia nigra, reduced α-Syn immunoreactivity in nigral DA neurons, and reduced small α-Syn aggregates (). Another study in 4L;C∗ mice reported that IFG did not alter the GlcCer and GlcSph accumulation, but attenuated disease progression and altered global expression profiles of brain mRNA and miRNAs (). Treating Drosophila manipulated to express human wild-type, N370S and L444P GBA1, with IFG resulted in decreased ER stress and preserved motor function, suggesting that IFG might have potential as a PD therapy ().
De La Mata et al. reported that a distinct iminosugar, NAdBT-AIJ restored mitochondrial dysfunction and GCase activity in L444P mice in combination with coenzyme Q10 (). Another pyrrolidine-based iminosugar, α-1-C-tridecyl-DAB (5j) was shown to function as a chaperone inhibitor of GCase enhancing enzyme activity at concentrations 10 times lower than IFG ().
Ambroxol
Ambroxol (ABX), a drug used to treat airway mucus hypersecretion and hyaline membrane disease in newborns, was found to be a pH-dependent, mixed-type inhibitor of GCase, and thus a potential therapy for GD. With its inhibitory activity maximal at neutral pH, ABX is found in the ER, and is undetectable at the acidic pH of lysosomes (). GCase activity was enhanced in ABX-treated GD fibroblasts and lymphoblasts. Furthermore, modeling studies indicated that ABX interacts with both active site and non-active site residues of GCase (). The tolerability and efficacy of ABX was evaluated in 12 patients with type 1 GD not receiving ERT. While only three patients who continued on ABX for a year had improved platelet counts and decreased organ volumes, the others remained stable, supporting the need for a larger clinical trial (Zimran et al., 2013). The chaperone activity and cytotoxicity of ABX was tested in vitro, demonstrating low cytotoxicity and significantly increased GCase activity in GD and GD+PD fibroblasts with different GD mutations, without any serious adverse effects (; ; ). Another study in GBA1-mutant fibroblasts showed that ABX enhanced GCase activity by increasing Sap C and LIMP-2 protein levels (). Testing in vivo efficacy of 12 days of ABX in wild-type, L444P carrier and transgenic mice overexpressing human α-Syn demonstrated increased brain GCase activity and decreased total and phosphorylated α-Syn levels (). In nonhuman primates, daily administration of ABX increased brain GCase activity, supporting clinical testing in humans (). In Drosophila melanogaster with a mutated GBA1b ortholog, treatment with ABX did not rescue GCase activity, but did ameliorate the unfolded protein response, inflammation and neuroinflammation, and enhance the life span (). Several pilot clinical studies of ABX were performed in patients with nGD (; ; ). One study in five patients with GD3 showed that high-dose oral ABX had good safety and tolerability, significantly increased lymphocyte GCase activity, permeated the blood–brain barrier, and decreased GlcSph levels in the cerebrospinal fluid. The investigators reported that myoclonus, seizures, and pupillary light reflex dysfunction improved, leading to the recovery of gross motor function in two patients (). Another study of the long-term safety and efficacy of combined high-dose ABX up to 21 mg/kg/day) and ERT in GD3 showed that during the first 2 years seizure frequency and neurocognitive function worsened, but after the ABX dosage was increased to 27 mg/kg/day, seizure frequency markedly decreased from the baseline, neurocognitive function improved and the drug was tolerated without severe adverse events (). However, these are primarily antidotal reports, and a double-blind placebo-control study is needed. ABX is currently being tested under a single-center phase II clinical trial in 75 subjects with mild to moderate PD by randomizing participants into ABX high-dose (1,050 mg/day), low-dose (525 mg/day), or placebo group (Silveira et al., 2019), and reasonable cerebrospinal fluid levels were attained ().
Non-Inhibitory Chaperones
A major limitation of inhibitory chaperones is that the chaperone activity must be balanced against the functional inhibition of GCase. In contrast, non-inhibitory chaperones can assist in the folding of mutant GCase in the ER and the translocation to lysosomes without interfering with the active site of the enzyme, and thus can restore enzyme activity in the lysosome. Several non-inhibitory compounds were identified by a high throughput screening (HTS) assay using an extract of spleen from a patient with GD as the source of mutant enzyme (). In this screen, saposin C and other potential cofactors were present in the extract, likely enhancing the detection of non-inhibitory chaperones. The activities of the compounds were confirmed in subsequent cell-based assays using patient-derived fibroblasts. The screen yielded novel pyrazolopyrimidine-based non-inhibitory pharmacological chaperones (). assessed the efficacy of one non-inhibitory chaperone identified by HTS as a drug candidate for GD or GBA1-PD. Since fibroblasts do not store GlcCer, monocyte-derived macrophages from 20 patients with GD and GD iPSC-differentiated macrophages were examined. The non-inhibitory chaperone, NCGC758, enhanced GCase activity, reduced glycolipid storage, and normalized chemotaxis and the production of reactive oxygen species in the macrophages. NCGC758 also reversed inflammatory defects in GD macrophages by inducing autophagy and reducing IL-1b secretion (). Another lead non-inhibitory small molecule, NCGC607, was tested in dopaminergic (DA) neurons differentiated from type 1 and 2 GD and GD+PD iPSCs (). NCGC607 restored GCase activity and protein levels, and reduced glycolipid storage in GD DA neurons, indicating its therapeutic potential for GD. In addition, NCGC607 reduced α-Syn levels in DA neurons from patients with parkinsonism, suggesting that NCGC607 or a derivative of this lead compound may have efficacy as a treatment for PD (). NCGC758 also reduced α-Syn levels and improved lysosomal function in iPSC-derived DA neurons differentiated from patients with GD and PD ().
Other Small Molecules
Histone deacetylase inhibitors (HDACi) have also been explored for the treatment of GD by modulating a GCase-associated ubiquitin–proteasome pathway (). It was shown that a known HDACi (SAHA) and a unique small-molecule HDACi (LB-205) rescued GCase levels and increased enzymatic activity in fibroblasts derived from patients with GD1 and GD2. It was further shown that HDACi inhibits the deacetylation of heat shock protein (HSP90), resulting in impaired recognition of the mutant peptide by HSP90, thus protecting GCase from degradation (Yang et al., 2013).
Recently, S-181, a new small-molecule capable of stabilizing wild-type GCase was developed. S-181 increased GCase activity in iPSC-derived DA neurons from patients with idiopathic PD, as well as in patients with PD carrying GBA1 mutation c.84dupG and mutations in other PD genes (). S-181 treatment in these DA neurons reversed pathogenic phenotypes including the reduced accumulation of oxidized dopamine. It was also shown in Table 1 that treating wild-type and heterozygous D409V mice with S-181 increased GCase activity in both, resulting in reduction of the lipid substrates and α-Syn in brain ().
TABLE 1
| Name of small molecules | Disease modeled | GBA1 mutations tested | Model organisms | Effect of small molecules | References |
| Inhibitory chaperones | |||||
| NN-DNJ | GD1 | N370S | Fibroblasts | Increased GCase activity | |
| α-1-C-Nonyl-DIX | GD1 | N370S | Fibroblasts | Increased GCase activity | |
| sp2-iminosugar | GD1 | F213I, N370S | Fibroblasts | Increased GCase activity | |
| nGD | L444P, G202R | DA neurons from iPSCs | Increased GCase activity and protein level | Tiscornia et al., 2013 | |
| Isofagomine | GD1 | N370S | Fibroblasts | Increased GCase activity | |
| nGD | L444P | Fibroblasts and lymphoblasts | Increased GCase activity Reduced GlcCer levels | ||
| nGD | L444P | Mouse | Increased GCase activity in relevant tissues | ||
| nGD | V394L/V394L + saposin C−/− | Mouse | Extended lifespan Increased GCase activity and protein levels Attenuation of proinflammatory response | Sun et al., 2011 | |
| nGD | V394L, D409H, and D409V | Mouse | Increased GCase activity in relevant tissues | Sun et al., 2012 | |
| PD | α-Syn overexpression | Mouse | Improved motor function Reduced α-Syn immunoreactivity Reduced α-Syn aggregates | ||
| nGD | V394L/V394L + saposin C−/− | Mouse | Extended lifespan Attenuation of proinflammatory response Altered expression of DEGs* | ||
| GBA1-PD | N370S, L444P | Drosophila | Decreased ER** stress Restored motor function | ||
| NAdBT-AIJ + coQ | nGD | L444P | Mouse | Restored mitochondrial dysfunction Increased GCase activity | |
| α-1-C-tridecyl-DAB | GD1 | N370S | Fibroblasts | Increased GCase activity | |
| Ambroxol | GD1 | N370S, F213I | Fibroblasts and lymphoblasts | Increased GCase activity and protein levels Reduced GlcCer levels | |
| GD1,2&3 | N370S, F213I, N188S, G193W, R120W | Fibroblasts | Increased GCase activity | ||
| GD1,2&3 | N370S, V394L, R120W, R415R, R131C | Fibroblasts | Increased GCase activity | ||
| GD1 and GBA1-PD | N370S, etc. | Fibroblasts | Increased GCase activity and protein levels increase GCase mRNA and TFEB mRNA | ||
| GBA1-PD and non-GBA1-PD | N370S, L444P | Fibroblasts, drosophila | Increased GCase activity Increased Sap C | ||
| PD | L444P, α-Syn overexpression | Mouse | Increased GCase activity in brains Reduced α-Syn levels | ||
| PD | wildtype | Non-human primate | Increased GCase activity in brains | ||
| nGD | C-terrminal 133aa deletion in GBAb | Drosophila | Reduced unfolded protein response Reduced neuroinflammation Enhanced lifespan | ||
| Non-inhibitory Chaperonea | |||||
| NCGC758 | GD1 GD2 | N370S, L444P, c.84dupG, IVS2+1 | Macrophages from iPSCs | Increased GCase activity Reduced GlcCer levels Recovered ROS*** production Improved chemotaxis | |
| NCGC758 | GD1 | N370S | Macrophages from iPSCs | Induced autophagy and Reduced IL-1β secretion | |
| NCGC758 | nGD | N370S, c.84dupG | DA neurons from iPSCs | Increased GCase activity Reduced α-Syn levels Improved lysosomal function | |
| NCGC607 | GD, GD with parkinsonism | N370S, c.84dupG, IVS2+1, L444P | DA neurons from iPSCs | Increased GCase activity Reduced GlcCer and GlcSph levels Reduced α-Syn levels | |
| Others | |||||
| LB-250 | GD | N370S, L444P | Fibroblasts | Inhibit histone deacetylase activity Increased GCase activity and protein levels | |
| S-181 | GBA1-PD and non-GBA1-PD | c.84dupG, wildtype | DA neurons from iPSCs | Increased GCase activity Reduced GlcCer levels Reduced the oxidized dopamine and α-Syn | |
| S-181 | GBA1-PD | D409V | Mouse | Reduced GlcCer and GlcSph levels in brain Reduced α-Syn levels in brain | |
Small molecules considered as therapeutics for GD and GBA1-associated PD.
*Differentially expressed brain mRNAs. **Endoplasmic reticulum. ***Reactive oxygen species.
Discussion
There are several FDA-approved ERT (Cerezyme, etc.) and SRT (Zaversca, etc.) drugs to treat GD. However, ERT does not have utility for GBA1-PD since it does not cross the blood-brain- barrier and since substrate accumulation in GBA1-PD is minimal, it is unlikely that SRT will be efficacious (Sidransky et al., 2019). Small molecule pharmacological chaperones have been developed to overcome these limitations. The first iminosugar developed, NN-DNJ, increased GCase activity in cells from patients with GD () by strong binding to GCase (Thirumal Kumar et al., 2019). However, NN-DNJ only increases enzymatic activity in lines with specific GBA1 mutations (; Thirumal Kumar et al., 2019) and also inhibits GlcCer synthase activity in a dose-dependent manner (). Isofagomine (IFG) appears to have more target-specific inhibition and broader pre-clinical efficacy in both in vitro and in vivo models of different types of GD and PD. However, like other inhibitory small molecule chaperones, IFG also causes dosage-dependent inhibition of GCase, limiting its clinical utility. A phase II clinical trial of IFG failed to improve clinical symptoms in patients with GD, likely due to dosing challenges. Ambroxol (ABX) has been evaluated as an inhibitory chaperone with fewer side effects and better efficacy, because its inhibitory effect does not occur at the low pH present in lysosomes. A recent comparative molecular docking analysis showed that ABX has more broad binding affinity toward GCase than NN-DNJ and other SRT drugs (Thirumal Kumar et al., 2019). A phase II clinical study of ABX for PD is currently underway (Silveira et al., 2019).
Non-inhibitory chaperones are highly attractive candidate drugs for the treatment of GD or GBA1-PD because they avoid the primary problem associated with inhibitory chaperones, the inhibitory competition with substrates of GCase in the lysosome. A few non-inhibitory chaperones identified by HTS were shown to have disease-reversing effects in cellular models of GD or GBA1-PD (, ). However, there are also difficulties in developing non-inhibitory chaperones. The binding of non-inhibitory chaperones to sites other than the active site makes it difficult to perform structure-guided optimization of drug efficacy and challenging to evaluate the potential activity of candidate molecules from HTS. To resolve this problem, visualizing the activity of endogenous levels of GCase in live cells is required. This might be achieved through the development of a fluorescence-based substrate probe representing GCase activity in lysosomes of live cells ().
To increase the likelihood of success in clinical trials, a properly designed pre-clinical drug testing strategy is essential. Thus, appropriate in vitro and in vivo disease models which mimic key features of the disease are cessary. DA neurons differentiated from patient iPSCs accumulate α-Syn and oxidized dopamine, and thus can be used to test the efficacy of small molecules for PD (; ). However, mouse models accurately replicating PD phenotypes are still needed. A previous study showed that mice carrying the L444P mutation had increased stability of over-expressed human wild-type and A53T mutant α-Syn (). However, the L444P mice did not demonstrate accumulation of α-Syn and there was no PD phenotypes in the L444P carrier mice (). While heterozygous L444P mice overexpressing mutant α-Syn had exacerbated motor deficits () and enhanced dopaminergic neurodegeneration (), it is not clear whether this phenotype can be used to establish drug efficacy, especially as in patients, the α-Syn levels are not as high, and the protein is not mutated. To identify and optimize candidate non-inhibitory chaperones, new methods for evaluating GCase activity in live cells and more appropriate GBA1-PD animal models need to be developed. Three dimensional in-vitro cell culture systems can be also considered for drug screening and preclinical validation of candidate drugs, because they more closely resembles the in-vivo cell environment than routine in-vitro cell culture ().
Statements
Author contributions
T-UH contributed to the conceptual idea, reviewed, analyzed the literature, and wrote the manuscript and table. RS assisted in compiling background material and in writing the manuscript. ES provided the conceptual idea, reviewed, and edited the manuscript.
Funding
This work was supported by the Intramural Research Programs of the National Human Genome Research Institute and the National Institutes of Health.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AflakiE.BorgerD. K.MoavenN.StubblefieldB. K.RogersS. A.PatnaikS.et al (2016a). A new glucocerebrosidase chaperone reduces α-synuclein and glycolipid levels in iPSC-derived dopaminergic neurons from patients with gaucher disease and parkinsonism.J. Neurosci.367441–7452. 10.1523/JNEUROSCI.0636-16.2016
2
AflakiE.MoavenN.BorgerD. K.LopezG.WestbroekW.ChaeJ. J.et al (2016b). Lysosomal storage and impaired autophagy lead to inflammasome activation in Gaucher macrophages.Aging Cell1577–88. 10.1111/acel.12409
3
AflakiE.StubblefieldB. K.ManiwangE.LopezG.MoavenN.GoldinE.et al (2014). Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs.Sci. Transl. Med.6:240ra273. 10.1126/scitranslmed.3008659
4
AmbrosiG.GhezziC.ZangagliaR.LevandisG.PacchettiC.BlandiniF. (2015). Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson’s disease cells.Neurobiol. Dis.82235–242. 10.1016/j.nbd.2015.06.008
5
BalestrinoR.SchapiraA. H. V. (2018). Glucocerebrosidase and Parkinson disease: molecular, clinical, and therapeutic implications.Neuroscientist24540–559. 10.1177/1073858417748875
6
Bendikov BarI.MaorG.FilocamoM.HorowitzM. (2013). Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase.Blood Cells Mol. Dis.50141–145. 10.1016/j.bcmd.2012.10.007
7
BennettL. L.TurcotteK. (2015). Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease.Drug Des. Devel. Ther.94639–4647. 10.2147/DDDT.S77760
8
BeutlerE.GrabowskiG. A. (2001). “Gaucher disease,” in The Metabolic & Molecular Bases of Inherited Disease, ed.ScriverC. R. (New York: McGraw-Hill), 3635–3668.
9
BurbullaL. F.JeonS.ZhengJ.SongP.SilvermanR. B.KraincD. (2019). A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson’s disease.Sci. Transl. Med.11:eaau6870. 10.1126/scitranslmed.aau6870
10
CabassoO.PaulS.DorotO.MaorG.KrivorukO.Pasmanik-ChorM.et al (2019). Drosophila melanogaster mutated in its GBA1b ortholog recapitulates neuronopathic gaucher disease.J. Clin. Med.8:1420. 10.3390/jcm8091420
11
CompainP.MartinO. R.BoucheronC.GodinG.YuL.IkedaK.et al (2006). Design and synthesis of highly potent and selective pharmacological chaperones for the treatment of Gaucher’s disease.Chembiochem71356–1359. 10.1002/cbic.200600217
12
DasguptaN.XuY. H.LiR.PengY.PandeyM. K.TinchS. L.et al (2015). Neuronopathic Gaucher disease: dysregulated mRNAs and miRNAs in brain pathogenesis and effects of pharmacologic chaperone treatment in a mouse model.Hum. Mol. Genet.247031–7048. 10.1093/hmg/ddv404
13
De La MataM.CotanD.Oropesa-AvilaM.Garrido-MaraverJ.CorderoM. D.Villanueva PazM.et al (2015). Pharmacological chaperones and coenzyme Q10 treatment improves mutant β-glucocerebrosidase activity and mitochondrial function in neuronopathic forms of gaucher disease.Sci. Rep.5:10903. 10.1038/srep10903
14
FishbeinI.KuoY. M.GiassonB. I.NussbaumR. L. (2014). Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation.Brain1373235–3247. 10.1093/brain/awu291
15
GeggM. E.BurkeD.HealesS. J.CooperJ. M.HardyJ.WoodN. W.et al (2012). Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains.Ann. Neurol.72455–463. 10.1002/ana.23614
16
GoldinE.ZhengW.MotabarO.SouthallN.ChoiJ. H.MaruganJ.et al (2012). High throughput screening for small molecule therapy for Gaucher disease using patient tissue as the source of mutant glucocerebrosidase.PLoS One7:e29861. 10.1371/journal.pone.0029861
17
GuptaN.OppenheimI. M.KauvarE. F.TayebiN.SidranskyE. (2011). Type 2 Gaucher disease: phenotypic variation and genotypic heterogeneity.Blood Cells Mol. Dis.4675–84. 10.1016/j.bcmd.2010.08.012
18
HenleyW. E.AndersonL. J.WyattK. M.NikolaouV.AndersonR.LoganS. (2014). The NCS-LSD cohort study: a description of the methods and analyses used to assess the long-term effectiveness of enzyme replacement therapy and substrate reduction therapy in patients with lysosomal storage disorders.J. Inherit. Metab. Dis.37939–944. 10.1007/s10545-014-9679-6
19
HorowitzM.Pasmanik-ChorM.BorochowitzZ.Falik-ZaccaiT.HeldmannK.CarmiR.et al (1998). Prevalence of glucocerebrosidase mutations in the Israeli Ashkenazi Jewish population.Hum. Mutat.12240–244. 10.1002/(sici)1098-1004(1998)12:4<240::aid-humu4>3.0.co;2-j
20
JungO.PatnaikS.MaruganJ.SidranskyE.WestbroekW. (2016). Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease.Expert Rev. Proteomics13471–479. 10.1080/14789450.2016.1174583
21
KatoA.NakagomeI.SatoK.YamamotoA.AdachiI.NashR. J.et al (2016). Docking study and biological evaluation of pyrrolidine-based iminosugars as pharmacological chaperones for Gaucher disease.Org. Biomol. Chem.141039–1048. 10.1039/c5ob02223a
22
KhannaR.BenjaminE. R.PellegrinoL.SchillingA.RigatB. A.SoskaR.et al (2010). The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of β-glucosidase.FEBS J.2771618–1638. 10.1111/j.1742-4658.2010.07588.x
23
KimY. M.YumM. S.HeoS. H.KimT.JinH. K.BaeJ. S.et al (2019). Pharmacologic properties of high-dose ambroxol in four patients with Gaucher disease and myoclonic epilepsy.J. Med. Genet.57124–131. 10.1136/jmedgenet-2019-106132
24
LanghansS. A. (2018). Three-Dimensional in vitro cell culture models in drug discovery and drug repositioning. Front. Pharmacol.9:6. 10.3389/fphar.2018.00006
25
LiebermanR. L.WustmanB. A.HuertasP.PoweA. C.PineC. W.KhannaR.et al (2007). Structure of acid β-glucosidase with pharmacological chaperone provides insight into Gaucher disease.Nat. Chem. Biol.3101–107. 10.1038/nchembio850
26
LuJ.YangC.ChenM.YeD. Y.LonserR. R.BradyR. O.et al (2011). Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease.Proc. Natl. Acad. Sci. U.S.A.10821200–21205. 10.1073/pnas.1119181109
27
LuanZ.HigakiK.Aguilar-MoncayoM.LiL.NinomiyaH.NanbaE.et al (2010). A fluorescent sp2-iminosugar with pharmacological chaperone activity for gaucher disease: synthesis and intracellular distribution studies.Chembiochem112453–2464. 10.1002/cbic.201000323
28
LuanZ.HigakiK.Aguilar-MoncayoM.NinomiyaH.OhnoK.Garcia-MorenoM. I.et al (2009). Chaperone activity of bicyclic nojirimycin analogues for Gaucher mutations in comparison with N-(n-nonyl)deoxynojirimycin.Chembiochem102780–2792. 10.1002/cbic.200900442
29
LuanZ.LiL.HigakiK.NanbaE.SuzukiY.OhnoK. (2013). The chaperone activity and toxicity of ambroxol on Gaucher cells and normal mice.Brain Dev.35317–322. 10.1016/j.braindev.2012.05.008
30
LukinaE.WatmanN.DragoskyM.LauH.Avila ArreguinE.RosenbaumH.et al (2019). Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial.Am. J. Hematol.9429–38. 10.1002/ajh.25300
31
MaegawaG. H.TropakM. B.ButtnerJ. D.RigatB. A.FullerM.PanditD.et al (2009). Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease.J. Biol. Chem.28423502–23516. 10.1074/jbc.M109.012393
32
MazzulliJ. R.ZunkeF.IsacsonO.StuderL.KraincD. (2016a). α-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models.Proc. Natl. Acad. Sci. U.S.A.1131931–1936. 10.1073/pnas.1520335113
33
MazzulliJ. R.ZunkeF.TsunemiT.TokerN. J.JeonS.BurbullaL. F.et al (2016b). Activation of β-glucocerebrosidase reduces pathological α-synuclein and restores lysosomal function in Parkinson’s patient midbrain neurons.J. Neurosci.367693–7706. 10.1523/JNEUROSCI.0628-16.2016
34
McNeillA.MagalhaesJ.ShenC.ChauK. Y.HughesD.MehtaA.et al (2014). Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.Brain1371481–1495. 10.1093/brain/awu020
35
Mena-BarraganT.Garcia-MorenoM. I.NanbaE.HigakiK.ConciaA. L.ClapesP.et al (2016). Inhibitor versus chaperone behaviour of D-fagomine, DAB and LAB sp(2)-iminosugar conjugates against glycosidases: a structure-activity relationship study in Gaucher fibroblasts.Eur. J. Med. chem.121880–891. 10.1016/j.ejmech.2015.08.038
36
Migdalska-RichardsA.DalyL.BezardE.SchapiraA. H. (2016). Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice.Ann. Neurol.80766–775. 10.1002/ana.24790
37
Migdalska-RichardsA.KoW. K. D.LiQ.BezardE.SchapiraA. H. V. (2017a). Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate.Synapse71:e21967. 10.1002/syn.21967
38
Migdalska-RichardsA.WegrzynowiczM.RusconiR.DeangeliG.Di MonteD. A.SpillantiniM. G.et al (2017b). The L444P Gba1 mutation enhances α-synuclein induced loss of nigral dopaminergic neurons in mice.Brain1402706–2721. 10.1093/brain/awx221
39
MistryP. K.BalwaniM.BarisH. N.TurkiaH. B.BurrowT. A.CharrowJ.et al (2018). Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.Blood Cells Mol. Dis.7171–74. 10.1016/j.bcmd.2018.04.001
40
MullinS.HughesD.MehtaA.SchapiraA. H. V. (2019). Neurological effects of glucocerebrosidase gene mutations.Eur. J. Neurol.26:e0388-29. 10.1111/ene.13837
41
MullinS.SmithL.LeeK.D’souzaG.WoodgateP.ElfleinJ.et al (2020). Ambroxol for the treatment of patients with parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial.JAMA Neurol.13:e194611. 10.1001/jamaneurol.2019.4611
42
MurphyK. E.GysbersA. M.AbbottS. K.TayebiN.KimW. S.SidranskyE.et al (2014). Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson’s disease.Brain137834–848. 10.1093/brain/awt367
43
NallsM. A.DuranR.LopezG.Kurzawa-AkanbiM.MckeithI. G.ChinneryP. F.et al (2013). A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies.JAMA Neurol.70727–735. 10.1001/jamaneurol.2013.1925
44
NaritaA.ShiraiK.ItamuraS.MatsudaA.IshiharaA.MatsushitaK.et al (2016). Ambroxol chaperone therapy for neuronopathic Gaucher disease: a pilot study.Ann. Clin. Transl. Neurol.3200–215. 10.1002/acn3.292
45
PastoresG. M.PatelM. J.FiroozniaH. (2000). Bone and joint complications related to Gaucher disease.Curr. Rheumatol. Rep.2175–180. 10.1007/s11926-000-0059-x
46
PatnaikS.ZhengW.ChoiJ. H.MotabarO.SouthallN.WestbroekW.et al (2012). Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase.J. Med. Chem.555734–5748. 10.1021/jm300063b
47
PawlinskiL.MaleckiM. T.Kiec-WilkB. (2018). The additive effect on the antiepileptic treatment of ambroxol in type 3 Gaucher patient. The early observation.Blood Cells Mol. Dis.68192–193. 10.1016/j.bcmd.2016.12.001
48
PoeweW.SeppiK.TannerC. M.HallidayG. M.BrundinP.VolkmannJ.et al (2017). Parkinson disease.Nat. Rev. Dis. Primers3:17013. 10.1038/nrdp.2017.13
49
RichterF.FlemingS. M.WatsonM.LemesreV.PellegrinoL.RanesB.et al (2014). A GCase chaperone improves motor function in a mouse model of synucleinopathy.Neurotherapeutics11840–856. 10.1007/s13311-014-0294-x
50
SalaG.MarinigD.ArosioA.FerrareseC. (2016). Role of chaperone-mediated autophagy dysfunctions in the pathogenesis of Parkinson’s disease.Front. Mol. Neurosci.9:157. 10.3389/fnmol.2016.00157
51
Sanchez-MartinezA.BeavanM.GeggM. E.ChauK. Y.WhitworthA. J.SchapiraA. H. (2016). Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models.Sci. Rep.6:31380. 10.1038/srep31380
52
SawkarA. R.ChengW. C.BeutlerE.WongC. H.BalchW. E.KellyJ. W. (2002). Chemical chaperones increase the cellular activity of N370S β -glucosidase: a therapeutic strategy for Gaucher disease.Proc. Natl. Acad. Sci. U.S.A.9915428–15433. 10.1073/pnas.192582899
53
SchiffmannR.FitzgibbonE. J.HarrisC.DevileC.DaviesE. H.AbelL.et al (2008). Randomized, controlled trial of miglustat in Gaucher’s disease type 3.Ann. Neurol.64514–522. 10.1002/ana.21491
54
SidranskyE. (2004). Gaucher disease: complexity in a “simple” disorder.Mol. Genet. Metab.836–15. 10.1016/j.ymgme.2004.08.015
55
SidranskyE. (2012). Gaucher disease: insights from a rare Mendelian disorder.Discov. Med.14273–281.
56
SidranskyE.ArkadirD.BauerP.DinurT.LopezG.RolfsA.et al (2019). Substrate reduction therapy for GBA1-associated Parkinsonism: are we betting on the wrong mouse?Mov. Disord.35228–230. 10.1002/mds.27903
57
SidranskyE.LopezG. (2012). The link between the GBA gene and parkinsonism.Lancet Neurol.11986–998. 10.1016/S1474-4422(12)70190-4
58
SidranskyE.NallsM. A.AaslyJ. O.Aharon-PeretzJ.AnnesiG.BarbosaE. R.et al (2009). Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease.N. Engl. J. Med.3611651–1661. 10.1056/NEJMoa0901281
59
SilveiraC. R. A.MackinleyJ.ColemanK.LiZ.FingerE.BarthaR.et al (2019). Ambroxol as a novel disease-modifying treatment for Parkinson’s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial.BMC Neurol.19:20. 10.1186/s12883-019-1252-3
60
SpillantiniM. G.SchmidtM. L.LeeV. M.TrojanowskiJ. Q.JakesR.GoedertM. (1997). α-synuclein in Lewy bodies.Nature388839–840. 10.1038/42166
61
StojkovskaI.KraincD.MazzulliJ. R. (2018). Molecular mechanisms of α-synuclein and GBA1 in Parkinson’s disease.Cell Tissue Res.37351–60. 10.1007/s00441-017-2704-y
62
SunY.LiouB.XuY. H.QuinnB.ZhangW.HamlerR.et al (2012). Ex vivo and in vivo effects of isofagomine on acid β-glucosidase variants and substrate levels in Gaucher disease.J. Biol. Chem.2874275–4287. 10.1074/jbc.M111.280016
63
SunY.RanH.LiouB.QuinnB.ZamzowM.ZhangW.et al (2011). Isofagomine in vivo effects in a neuronopathic Gaucher disease mouse.PLoS One6:e19037. 10.1371/journal.pone.0019037
64
SurmeierD. J.ObesoJ. A.HallidayG. M. (2017). Parkinson’s disease is not simply a prion disorder.J. Neurosci.379799–9807. 10.1523/JNEUROSCI.1787-16.2017
65
TaguchiY. V.LiuJ.RuanJ.PachecoJ.ZhangX.AbbasiJ.et al (2017). Glucosylsphingosine promotes α-synuclein pathology in mutant GBA-associated Parkinson’s disease.J. Neurosci.379617–9631. 10.1523/JNEUROSCI.1525-17.2017
66
Thirumal KumarD.IyerS.ChristyJ. P.SivaR.TayubiI. A.GeorgeP.et al (2019). A comparative computational approach toward pharmacological chaperones (NN-DNJ and ambroxol) on N370S and L444P mutations causing Gaucher’s disease.Adv. Protein Chem. Struct. Biol.114315–339. 10.1016/bs.apcsb.2018.10.002
67
TiscorniaG.VivasE. L.MatalongaL.BerniakovichI.Barragan MonasterioM.EguizabalC.et al (2013). Neuronopathic Gaucher’s disease: induced pluripotent stem cells for disease modelling and testing chaperone activity of small compounds.Hum. Mol. Genet.22633–645. 10.1093/hmg/dds471
68
ValayannopoulosV. (2013). Enzyme replacement therapy and substrate reduction therapy in lysosomal storage disorders with neurological expression.Handb. Clin. Neurol.1131851–1857. 10.1016/B978-0-444-59565-2.00055-1
69
WeissK.GonzalezA.LopezG.PedoeimL.GrodenC.SidranskyE. (2015). The clinical management of Type 2 Gaucher disease.Mol. Genet. Metab.114110–122. 10.1016/j.ymgme.2014.11.008
70
YangC.RahimpourS.LuJ.PacakK.IkejiriB.BradyR. O.et al (2013). Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones.Proc. Natl. Acad. Sci. U.S.A.110966–971. 10.1073/pnas.1221046110
71
YapT. L.GruschusJ. M.VelayatiA.WestbroekW.GoldinE.MoavenN.et al (2011). α-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases.J. Biol. Chem.28628080–28088. 10.1074/jbc.M111.237859
72
ZimranA.AltarescuG.ElsteinD. (2013). Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease.Blood Cells Mol. Dis.50134–137. 10.1016/j.bcmd.2012.09.006
73
ZimranA.GoldblattJ.SzerJ. (2018). Should eliglustat be first line therapy for patients with type 1 Gaucher disease? Definitions of safety and efficacy.Blood Cells Mol. Dis.6814–16. 10.1016/j.bcmd.2017.09.003
Summary
Keywords
gaucher disease, Parkinson disease, lysosome, glucocerebrosidase, GBA1, small molecule chaperones
Citation
Han T-U, Sam R and Sidransky E (2020) Small Molecule Chaperones for the Treatment of Gaucher Disease and GBA1-Associated Parkinson Disease. Front. Cell Dev. Biol. 8:271. doi: 10.3389/fcell.2020.00271
Received
25 January 2020
Accepted
30 March 2020
Published
19 May 2020
Volume
8 - 2020
Edited by
Miguel Weil, Tel Aviv University, Israel
Reviewed by
Pervin Rukiye Dincer, Hacettepe University, Turkey; Mia Horowitz, Tel Aviv University, Israel
Updates
Copyright
© 2020 Han, Sam and Sidransky.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ellen Sidransky, sidranse@mail.nih.gov
This article was submitted to Molecular Medicine, a section of the journal Frontiers in Cell and Developmental Biology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.